The High-Risk Plaque Initiative: Primary Prevention of Atherothrombotic Events in the Asymptomatic Population

[1]  E. Arias,et al.  United States life tables eliminating certain causes of death, 1999-2001. , 2013, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[2]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[3]  Martin O'Flaherty,et al.  Rapid mortality falls after risk-factor changes in populations , 2011, The Lancet.

[4]  M. Pencina,et al.  Performance of current guidelines for coronary heart disease prevention: optimal use of the Framingham-based risk assessment. , 2011, Atherosclerosis.

[5]  A. Khera,et al.  Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association , 2011, Circulation.

[6]  Nicholas J Wald,et al.  Assessing risk factors as potential screening tests: a simple assessment tool. , 2011, Archives of internal medicine.

[7]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[8]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[9]  Vl Roger,et al.  American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update : a report from the American Heart Association , 2011 .

[10]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Circulation.

[11]  Teri A Manolio,et al.  Genomewide association studies and assessment of the risk of disease. , 2010, The New England journal of medicine.

[12]  V. Fuster,et al.  The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease--study design and objectives. , 2010, American heart journal.

[13]  V. Fuster,et al.  Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? , 2010, Journal of the American College of Cardiology.

[14]  Olli Saarela,et al.  Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts: The MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) Biomarker Project , 2010, Circulation.

[15]  V. Fuster,et al.  Early identification of atherosclerotic disease by noninvasive imaging , 2010, Nature Reviews Cardiology.

[16]  Eric Boerwinkle,et al.  Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. , 2010, Journal of the American College of Cardiology.

[17]  E. Falk,et al.  Risk factors for near-term myocardial infarction in apparently healthy men and women. , 2010, Clinical chemistry.

[18]  Jeffrey L. Anderson,et al.  ACCF / AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults , 2010 .

[19]  J. J. Rivera,et al.  Relationship of Carotid Distensibility and Thoracic Aorta Calcification: Multi-Ethnic Study of Atherosclerosis , 2009, Hypertension.

[20]  V. Fuster,et al.  The CVD paradox: mortality vs prevalence , 2009, Nature Reviews Cardiology.

[21]  R. Detrano,et al.  Association of electrocardiographic abnormalities with coronary artery calcium and carotid artery intima-media thickness in individuals without clinical coronary heart disease (from the Multi-Ethnic Study of Atherosclerosis [MESA]). , 2009, The American journal of cardiology.

[22]  Hirofumi Anno,et al.  Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. , 2009, Journal of the American College of Cardiology.

[23]  Jordi Castellsague,et al.  Positive predictive value of ICD‐9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database , 2008, Pharmacoepidemiology and drug safety.

[24]  Zahi A. Fayad,et al.  Imaging of atherosclerotic cardiovascular disease , 2008, Nature.

[25]  C. Carlson,et al.  USF1 Gene Variants, Cardiovascular Risk, and Mortality in European Americans: Analysis of Two US Cohort Studies , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[26]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) , 2007 .

[27]  Shah Ebrahim,et al.  Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .

[28]  W. Kerwin,et al.  The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. , 2007, Radiology.

[29]  Qiong Yang,et al.  The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. , 2007, American journal of epidemiology.

[30]  M. Lauer.  Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. , 2007, JAMA.

[31]  J. Ware.  The limitations of risk factors as prognostic tools. , 2006, The New England journal of medicine.

[32]  N. Wald,et al.  The efficacy of combining several risk factors as a screening test , 2005, Journal of medical screening.

[33]  Zahi A Fayad,et al.  Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. , 2005, Journal of the American College of Cardiology.

[34]  Zahi A Fayad,et al.  Atherothrombosis and high-risk plaque: part I: evolving concepts. , 2005, Journal of the American College of Cardiology.

[35]  C. Kooperberg,et al.  Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. , 2004, American journal of epidemiology.

[36]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[37]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[38]  Antonio Colombo,et al.  Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. , 2004, European heart journal.

[39]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[40]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[41]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[42]  N J Wald,et al.  A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.

[43]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[44]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[45]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[46]  S. Moore,et al.  Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.